MedTrace Logo

Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects

NCT00388609 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 705

Last updated 2010-09-17

No results posted yet for this study

Summary

The purpose of this study is to learn if BMS-646256 can cause weight loss in men and women who are:

* overweight with high blood pressure or high cholesterol or
* obese

The safety of this treatment will also be studied

Conditions

Interventions

DRUG

BMS-646256

Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)

DRUG

Placebo

Tablet, Oral, Once daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2007-09-30
Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00388609 on ClinicalTrials.gov